The objective response rate (ORR) was 71.1%, and the median duration of response (mDoR) was 11.1 months among patients with lung adenocarcinoma harboring uncommon EGFR mutations, namely G719X, L861Q, and S761I.5 The gene discussed is EGFR; the disease is lung adenocarcinoma.